Regulatory science in Europe: the case of schizophrenia trials

Lancet. 2013 Oct 12;382(9900):1234-5. doi: 10.1016/S0140-6736(13)60255-X. Epub 2013 Jun 21.

Authors

Corrado Barbui¹, Irene Bighelli

Affiliation

¹ WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Public Health and Community Medicine, Section of Psychiatry, University of Verona, 37134 Verona, Italy. [email protected]

PMID: 23791471
DOI: 10.1016/S0140-6736(13)60255-X

No abstract available

MeSH terms

Antipsychotic Agents / therapeutic use*
Clinical Trials, Phase III as Topic / legislation & jurisprudence
Clinical Trials, Phase III as Topic / methods
Drug Approval
Europe
Government Agencies
Humans
Practice Guidelines as Topic
Schizophrenia / drug therapy*

Substances

Antipsychotic Agents